ESMO 2020 Adjuvant therapy with osimertinib significantly reduces CNS disease recurrence in patients wit... Read more
CongressUpdate Lorlatinib as a first-line therapy for ALK-positive non-small cell lung cancer patients Read more
CongressUpdate Nivolumab plus cabozantinib as first-line treatment for advanced renal cell carcinoma Read more
ESMO 2020 Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective o... Read more